The reporting sensitivities of two passive surveillance systems for vaccine adverse events
about
The average cost of measles cases and adverse events following vaccination in industrialised countries.Product review on the JE vaccine IXIAROMonitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience.Adverse events following pandemic A (H1N1) 2009 monovalent vaccines in pregnant women--Taiwan, November 2009-August 2010.A retrospective population-based study on seizures related to childhood vaccination.Motor palsies of cranial nerves (excluding VII) after vaccination: reports to the US Vaccine Adverse Event Reporting System.Methods of ensuring vaccine safety.Using electronic medical records to enhance detection and reporting of vaccine adverse events.Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010Adverse events after recombinant human BMP2 in nonspinal orthopaedic procedures.Active surveillance for adverse events following immunization.The Costs and Valuation of Health Impacts of Measles and Rubella Risk Management Policies.Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study.Adverse event reports following yellow fever vaccination, 2007-13.Typhoid fever in travelers: who should be targeted for prevention?Advanced Clinical Decision Support for Vaccine Adverse Event Detection and Reporting.A Review of Dietary Supplement Adverse Event Report Data From the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004-2013.Emergence of Legionella pneumophila Pneumonia in Patients Receiving Tumor Necrosis Factor- Antagonists
P2860
Q24804057-9FF1DA60-4D68-4E71-8E27-5848EE3AA63BQ26866171-32CF1FA4-6A10-4661-8760-8A9C1C963DA2Q30367585-54682F44-73AB-4D88-AEE9-759505EE2356Q30406112-3C2AED44-4B58-4B39-8A89-BF3965F5665FQ33160174-719817CD-3795-44F5-A95E-0AFCC62435F0Q34290826-02084249-1820-497A-BF08-FA10B480D927Q35193420-DF19BDE0-01F5-4F12-B646-DAA90A4B4A47Q36404523-AF072A3E-872E-449D-A212-9A61BE359787Q36540764-BAAD8EB4-C514-4915-BF67-101BBC164CE9Q36732299-BE92630A-AD28-4B60-B2D7-9FC8FDC01B59Q38172268-AE20E2A1-8F33-4781-B26A-E71820562479Q38561977-476602D3-951F-4B67-AFB1-EC6D385E1D07Q39650695-76CBA120-7E27-4DF3-91B3-B90E0CF51FADQ40098397-860D97E7-38DA-4C6B-A04B-9AC30D0748A8Q40528115-8808992D-4EEA-4DB9-9C1A-7FB19CCEBBEBQ41172092-39D112DE-19DB-4502-A642-3BC3AAAFE7D2Q47420209-A9EF3A44-BBCE-4963-8C46-EFCFF49B3C19Q57779961-C097A9B8-D664-40BF-A7C5-2346BD618799
P2860
The reporting sensitivities of two passive surveillance systems for vaccine adverse events
description
im Dezember 1995 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 1995
@uk
name
The reporting sensitivities of ...... ems for vaccine adverse events
@en
The reporting sensitivities of ...... ems for vaccine adverse events
@nl
type
label
The reporting sensitivities of ...... ems for vaccine adverse events
@en
The reporting sensitivities of ...... ems for vaccine adverse events
@nl
prefLabel
The reporting sensitivities of ...... ems for vaccine adverse events
@en
The reporting sensitivities of ...... ems for vaccine adverse events
@nl
P356
P1476
The reporting sensitivities of ...... ems for vaccine adverse events
@en
P2093
P304
P356
10.2105/AJPH.85.12.1706
P407
P577
1995-12-01T00:00:00Z